THE ROLE OF MICRORNAS IN THE REGULATION OF MELANOMA SIGNALING PATHWAYS

DOI: https://doi.org/None

Kit O.I., Vodolazhsky D.I., Timoshkina N.N.

The frequency of reported cases of melanoma and related mortality rates continue to increase worldwide. The study of the basic mechanisms of both the initiation and development of this highly aggressive tumour proves to be important for the identification of therapeutic purposes and prognosis of the disease. Epigenetic changes in the regulation of gene expression level are early events in the initiation of sporadic cases of oncogenesis and tumour progression. The review summarizes data on the contribution of miRNAs in the process of oncogenic activity of certain cell signalling pathways by the changing of the level of known oncogenes and onco-suppressor in melanoma. There are provided examples of changes in the expression of several miRNAs, as well as their potential for the targeted therapy of melanoma.
Keywords: 
miRNA, gene expression, melanoma
Список литературы: 
  1. Friedman R. J., Heilman E. R. The pathology of malignant melanoma. Dermatol. Clin. 2002; 20: 659–76.
  2. Lens M. B., Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br. J. Dermatol. 2004; 150: 179–85.
  3. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. A Cancer Journal for Clinicians. 2013; 63 (1); 11–30.
  4. Sostoyanie onkologicheskoy pomoshhi naseleniyu Rossii v 2013 godu. Pod red. Kaprina A.D., Starinskogo V.V., Petrovoy G.V. M.: FGBU «MNIOI im. P.A. Gercena» Minzdrava Rossii. 2014; 235. [The state of cancer care in Russia in 2013. Ed. Kaprin A.D., Starinskij V.V., Petrova G.V. M.: FGBU «MNIOI them. P.A. Herzen» Russian Ministry of Health. 2014; 235 (in Russian)]
  5. Tsao H., Chin L., Garraway L.A., Fisher D.E. Melanoma: from mutations to medicine. Genes Dev. 2012; 26 (11): 1131–55.
  6. Caramuta S.,Egyházi S., Rodolfo M., Witten D., Hansson J., Larsson C., Lui W.O. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J. Invest. Dermatol. 2010; 130 (8): 2062–70.
  7. Tarasov V.A., Matishov D.G., Shin E.F., Boyko N.V., Timoshkina N.N., Mahotkin M.A., Lomonosov A.M., Kirpiy A.A., Kit O.I., Maksimov A.Yu. Aberrantnaya e`kspressiya mikroRNK pri razvitii zlokachestvennyh opuholey tolstoy kishki. Genetika. 2014; 50 (10): 1232–44. [Tarasov V.A., Matishov D.G., Shin E.F., Boiko N.V., Timoshkina N.N., Makhotkin M.A., Lomonosov A.M., Kirpii A.A., Kit O.I., Maksimov A.Yu. Coordinated Aberrant Expression of miRNAs in Colon Cancer. Russian J. of Genetics. 2014; 50 (10): 1090–101 (in Russian)]
  8. Chan E., Patel R.,Nallur S., Ratner E., Bacchiocchi A., Hoyt K., Szpakowski S., Godshalk S., Ariyan S., Sznol M., Halaban R., Krauthammer M., Tuck D., Slack F.J., Weidhaas J.B. MicroRNA signatures differentiate melanoma subtypes. Cell Cycle. 2011; 10 (11): 1845–52.
  9. Griewank, K.G., Ugurel, S., Schadendorf, D., Paschen A. New developments in biomarkers for melanoma. Curr Opin Oncol. 2013; 25 (2): 145–51.
  10. Müller D.W., Bosserhoff A.K. Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene. 2008; 27 (52): 6698–706.
  11. Schultz J., Lorenz P., Gross G., Ibrahim S., Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 2008; 18 (5): 549–57.
  12. Chen J., Zhang X., Lentz C., Abi-Daoud M., Paré G.C., Yang X., Feilotter H.E., Tron V.A. miR-193b Regulates Mcl-1 in Melanoma. Am J Pathol. 2011; 179 (5): 2162–8.
  13. NoguchiS., Mori T., Hoshino Y., Yamada N., Nakagawa T., Sasaki N., Akao Y., Maruo K. Comparative study of anti-oncogenic microRNA-145 in canine and human malignant melanoma. J. Vet Med. Sci. 2012; 74 (1): 1–8.
  14. Felicetti F., Errico M.C., Bottero L., Segnalini P., Stoppacciaro A., Biffoni M., Felli N., Mattia G., Petrini M., Colombo M.P., Peschle C., Carè A. The promyelocyticleukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res. 2008; 68: 2745–54.
  15. GarofaloM., Di Leva G., Romano G., Nuovo G., Suh S.S., Ngankeu A., Taccioli C., Pichiorri F., Alder H., Secchiero P., Gasparini P., Gonelli A., Costinean S., Acunzo M., Condorelli G., Croce C.M. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 2009; 16 (6): 498–509.
  16. Igoucheva O., Alexeev V. MicroRNA-dependent regulation of cKit in cutaneous melanoma. Biochemical and biophysical research communications. 2009; 379 (3): 790–4.
  17. Dar A.A., Majid S., de Semir D., Nosrati M., Bezrookove V., Kashani-Sabet M. miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J. Biol. Chem. 2011; 286: 16606–14.
  18. Liu S., Kumar S.M., Lu H., Liu A., Yang R., Pushparajan A. Guo W., Xu X. MicroRNA-9 up-regulates E-cadherin through inhibition of NF-KappaB1-Snail1 pathway in melanoma. J. Pathol. 2012; 226 (1): 61–72.
  19. Forloni M., Dogra S.M., Dong Y., Conte D.Jr, Ou J., Zhu L.J., Deng A., Mahalingam M., Green M.R., Waiapeyee N. miR-146a promotes the initiation and progression of melanoma by activating Notch signaling. Elife. 2014; 3: e01460.
  20. Levati L., Alvino E., Pagani E., Arcelli D., Caporaso P., Bondanza S., D’Atri S. Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155. International Journal of Oncology. 2009; 35 (2): 393–400.
  21. Glud M., Rossing M., Hother C., Holst L., Hastrup N., Nielsen F.C., Gniadecki R., Drzewiecki K.T.Downregulation of miR-125b in metastatic cutaneous malignant melanoma. Melanoma Res. 2010; 20 (6): 479–84.
  22. Glud M., Manfé V., Biskup E., Holst L., Dirksen A.M., Hastrup N., Nielsen F.C., Drzewiecki K.T., Gniadecki R. MicroRNA miR-125b induces senescence in human melanoma cells. Melanoma Res. 2011; 21 (3): 253–6.
  23. Satzger I., Mattern A., Kuettler U., Weinspach D., Voelker B., Kapp A., Gutzmer R. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma International journal of cancer. Journal international du cancer. 2010; 126 (11): 2553–62.
  24. Penna E., Orso F., CiminoD.,Tenaglia E., Lembo A., Quaglino E., Poliseno L., Haimovic A., Osella-Abate S., De Pittà C., Pinatel E., Stadler M.B., Provero P., Bernengo M.G., Osman I., Taverna D. microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J. 2011; 30: 1990–2007.
  25. Streicher K.L., Zhu W., Lehmann K.P., Georgantas R.W., Morehouse C.A., Brohawn P., Yao Y. A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene. 2012; 3 1(12): 1558-70.
  26. Segura M.F., Hanniford D., Menendez S., Reavie L., Zou X., Diaz S.A., Zakrzewski J., Blochin E., Rose A., Bogunovic D., Polsky D., Wei J., Lee P., Belitskava-Levy I., Bhardwai N., Osman I., Hernando E. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc. Natl. Acad. Sci. U.S.A. 2009; 106 (6): 1814–9.
  27. Yang C.H., Yue J., Pfeffer S.R., Handor C.R., Pfeffer L.M. MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. J. Biol. Chem. 2011; 286: 39172–8.
  28. Jiang L., Lv X., Li J., Li J., Li X., Li W., Li Y. The status of microRNA-21 expression and its clinical significance in human cutaneous malignant melanoma. ActaHistochem. 2012; 114 (6): 582–8.
  29. Jin L., Hu W.L., Jiang C.C., Wang J.X., Han C.C., Chu P., Zhang L.J., Thorne R.F., Wilmott J., Scolyer R.A., Hersey P., Zhang X.D., Wu M. MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. PNAS. 2011; 108 (38): 15840–5.
  30. Loercher A.E., Tank E.M., Delston R.B., Harbour J.W. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J. Cell. Biol. 2005; 168: 35–40.
  31. Carreira S., Goodall J., Denat L., Rodriguez M., Nuciforo P.,Hoek K.S., Testori A.,Larue L.,Goding C.R. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev. 2006; 20: 3426–39.
  32. Boyle G.M., Woods S.L.,Bonazzi V.F., Stark M.S., Hacker E., Aoude L.G.,Dutton-Regester K., Cook A.L.,Sturm R.A., Hayward N.K. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res. 2011; 24 (3): 525–37.
  33. Heinemann A., Zhao F.,Pechlivanis S., Eberle J.,Steinle A., Diederichs S.,Schadendorf D., Paschen A. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res. 2012; 72: 460–71.
  34. Gaziel-Sovran A., Segura M.F., Di Micco R., Collins M.K., Hanniford D., de Miera E.VS., Rakus J.F., Dankert J.F., Shang S., Kerbel R.S. miR-30b/30d regulation of GalNActransferases enhances invasion and immunosuppression during metastasis. Cancer Cell. 2011; 20 (1): 1041–18.
  35. Chiang A.C., Massague J. Molecular basis of metastasis. N. Engl. J. Med. 2008; 359 (26): 2814–23.
  36. Fu T.Y., Chang C.C., Lin C.T., Lai C.H., Peng S.Y., Ko Y.J., Tang P.C. Let-7b-mediated suppression of basigin expression and metastasis in mouse melanoma cells. Exp. Cell. Res. 2011; 317 (4): 445–51.
  37. Migliore C., Petrelli A., Ghiso S., Capparuccia L., Eramo A., Comoglio P.M., Giordano S. MicroRNAs impair MET-mediated invasive growth. Cancer Res. 2008; 68: 10128–36.
  38. Mazar J., DeYoung K., Khaitan D., Meister E., Almodovar A., Goydos J., Ray A., Perera R.J. The regulation of miRNA-211 expression and its role in melanoma cell invasiveness. PLoS ONE. 2010; 5:e13779.
  39. Greenberg E., Hajdu S., Nemlich Y., Cohen R., Itzhaki O., Jacob-Hirsch J., Besser M.J., Schachter J., Markel G. Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex. Open Biol. 2014; 4: 140030.
  40. Saito Y., Liang G., Egger G., Friedman J.M., Chuang J.C., Coetzee G.A., Jones P.A. Specific activation of microRNA-127 with downregulation of the proto- oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell. 2006; 9 (6): 435–43.
  41. Kunej T., Godnic I., Ferdin J., Horvat S., Dovc P., Calin G.A. Epigenetic regulation of microRNAs in cancer: an integrated review of literature. Mutat Res. 2011; 717: 77–84.
  42. Baer C., Claus R., Frenzel L.P., Zucknick M., Park Y.J., Gu L., Weichenhan D., Fischer M., Pallasch C.P., Herpel E., Rehli M., Byrd J.C., Wendtner C.M., Plass C. Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. Cancer Res. 2012; 72 (15): 3775–85.
  43. Cai X., Hagedorn C.H., Cullen B.R. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA. 2004; 10: 1957–66.
  44. Fujita S., Ito T., Mizutani T., Minoguchi S., Yamamichi N., Sakurai K., Iba H. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol. 2008; 378 (3): 492–504.
  45. Kanemaru H., Fukushima S., Yamashita J., Honda N., Oyama R., Kakimoto A., Masuguchi S., Ishihara T., Inoue Y., Jinnin M., Ihn H. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci. 2011; 61 (3): 187–93.
  46. Leidinger P.,Keller A., Borries A., Reichrath J., Rass K., Jager S.U., Lenhof H.P., Meese E. High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer. 2010; 10: 262.
  47. Segura M.F., Belitskaya-Lévy I., Rose A.E., Zakrzewski J., Gaziel A., Hanniford D., Darvishian F., Berman R.S., Shapiro R.L., Pavlick A.C., Osman I., Hernando E. Melanoma MicroRNA signature predicts post-recurrence survival. Clin Cancer Res. 2010; 16 (5): 1577–86.
  48. Nguyen T., Kuo C., Nicholl M.B., Sim M.S., Turner R.R., Morton D.L., Hoon D.S. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics. 2011; 6 (3): 388–94.
  49. Fleming N.H., Zhong J., Da Silva I.E.D.P., de Miera E.V, Brady B.G., Han S.W., Hanniford D., Wang J., Shapiro R.L., Hernando E., Osman I.Serum-based miRNAs in the predictionanddetection of recurrencein melanomapatients. Cancer. 2015; 121 (1): 51–9.
  50. Huynh C., Segura M.F., Gaziel-Sovran A., Menendez S., Darvishian F., Chiriboga L., Levin B., Meruelo D., Osman I., Zavadil J., Marcusson E.G., Hernando E. Efficient in vivo microRNA targeting of liver metastasis. Oncogene. 2011; 30 (12): 148